Advances in Immunosupressive Therapy for Solid Organ Transplantation
Long-Term Management Strategies to Improve Patient Outcomes
Management Guidelines
2012 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation
KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients, 2009
General Resources
American Society of Transplantation
The American Society of Transplantation was founded in 1982 and is an organization of more than 3000 professionals dedicated to advancing the field of transplantation and improving patient care by promoting research, education, advocacy, and organ donation.
The Transplantation Society
The Transplantation Society is a Non-Governmental Organization (NGO) which serves as an international forum for the world-wide advancement of organ transplantation.
The National Kidney Foundation
The National Kidney Foundation is the leading organization in the U.S. dedicated to the awareness, prevention and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk.
American Liver Foundation
The American Liver Foundation was created in 1976 by the American Association for the Study of Liver Disease (AASLD) to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease.
Suggested Readings
Immune monitoring post liver transplant.
Sood S, Testro AG. World J Transplant. 2014;4(1):30-39.
Immunosuppressive drug therapy.
Hartono C, et al. Cold Spring Harb Perspect Med. 2013;3(9):a015487.
Calcineurin inhibitor–free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized Spare-the-Nephron Trial.
Teperman L, et al. Liver Transpl. 2013;19:675-689.
Are calcineurin inhibitors-free regimens ready for prime time?
Vincenti F. Kidney Int. 2012;82(10):1054-1060.
TOR signaling in growth and metabolism.
Wullschleger S, et al. Cell. 2006;124(3):471-484.
Review of the proliferation inhibitor everolimus.
Nashan B. Expert Opin Investig Drugs. 2002;11(12):1845-1857.
Sirolimus: its discovery, biological properties, and mechanism of action.
Sehgal SN. Transplant Proc. 2003;35(suppl 3):7S-14S.
Identifying biomarkers as diagnostic tools in kidney transplantation.
Mas VR, et al. Expert Rev Mol Diagn. 2011;11(2):183-196.
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts.
Suthanthiran M, et al. N Engl J Med. 2013;369(1):20-31.
Long-term Management Strategies to Improve Patient Outcomes
Relevant Resources
Improved Diagnostic and Management Strategies
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates & Discussions on the Evolving Role of JAK Inhibitors
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
